Written by a board-certified emergency physician and founder of DevotedDOC, a physician-owned national telemedicine organization, drawing on more than 120,000 telemedicine visits. This article is for education and is not a substitute for individual medical advice.

If you or someone you love is in crisis right now, call or text 988 (Suicide & Crisis Lifeline) or call SAMHSA’s free, confidential helpline at 1-800-662-HELP (4357), available 24/7. If someone is unresponsive or not breathing, call 911 and give naloxone if available.

It is 2:40 a.m. in an emergency department somewhere in America. A 34-year-old is waking up from a naloxone reversal. The overdose was fentanyl—it almost always is now. The team did everything right: airway protected, vitals stabilized, withdrawal assessed, buprenorphine offered and started, a referral printed, a follow-up appointment listed on the discharge paperwork.

Then the patient walks out the sliding doors into the dark, holding a piece of paper, and the most dangerous 72 hours of their life begin.

As emergency physicians, we have gotten remarkably good at the first half of this story. Over the past decade, emergency department (ED)-initiated buprenorphine has moved from a radical idea to an evidence-based standard endorsed by the American College of Emergency Physicians. What we have not solved is the second half: what happens after discharge. Patients started on treatment in the ED routinely have nowhere to land for days or weeks—and the data, and every clinician’s lived experience, tell us that the first 24 to 72 hours are exactly when recovery is won or lost.

We call it the 72-hour cliff. This article explains why the cliff exists, what the evidence says about crossing it, and why rapid telemedicine follow-up—same-day or next-day virtual visits with an addiction-trained physician—is emerging as the most practical bridge. It is written for three readers at once: the patient searching “what happens after the ER” at 3 a.m., the emergency physician or hospital leader trying to fix a broken handoff, and the health system, employer, or public health program looking for a scalable answer to the continuity problem.

One idea runs through everything that follows: the emergency department successfully starts treatment—telemedicine doesn’t replace the ED, it completes it.

If You Just Left the Emergency Room: Start Here

If you were treated in an ER for an overdose, fentanyl exposure, opioid withdrawal, or anything related to opioid use, here is what matters most right now:

• Your overdose risk is highest in the next few days. After an overdose or even a short gap in use, your tolerance drops. The same amount that felt “normal” before can now be fatal—especially with fentanyl, which dominates the illicit supply.
• Medication works. Buprenorphine (often known by the brand name Suboxone) and methadone are the most effective treatments we have for opioid use disorder. They roughly halve the risk of death when people stay on them, and they treat withdrawal within hours, not weeks.
• The ER can start your medication—and a doctor can continue it by phone or video, often the same day. Since 2023, any physician can prescribe buprenorphine; the old “X-waiver” requirement is gone. Federal telemedicine flexibilities have continued to allow buprenorphine treatment to begin and continue through telehealth visits, though rules continue to evolve—a legitimate telemedicine practice will confirm what applies in your state.
• Keep naloxone (Narcan) with you and make sure someone close to you knows how to use it. It is available without a prescription.
• You do not have to be “ready” in some perfect way. You do not need to hit bottom, quit everything at once, or prove anything. You need a next appointment within 24–72 hours. That’s it. That is the whole first step.

Also, if your discharge paperwork lists a clinic that can’t see you for two weeks, don’t wait. Instead, consider a same-day or next-day virtual appointment for medication-assisted treatment. Many insurance plans, including Medicaid plans, cover these visits, and transparent cash pricing is also common. The rest of this article explains why speed matters so much.

The Problem: The ED Is America’s Front Door for Addiction—and the Front Door Opens Onto a Cliff

According to the Centers for Disease Control and Prevention (CDC), approximately 105,000 Americans died from a drug overdose in 2023, and nearly 80,000 of those deaths involved opioids. While overdose deaths have declined from their peak of more than 110,000 per year, the toll remains staggering and continues to exceed deaths from car crashes and firearms combined, driven overwhelmingly by illicitly manufactured fentanyl.

For a huge share of these patients, the emergency department is the only part of the health system they touch. They arrive after an overdose reversed by EMS, in withdrawal after trying to quit alone, with an abscess or endocarditis from injection use, or simply because there was nowhere else open at 2 a.m. Emergency clinicians see the epidemic at point-blank range—and the ED visit itself is a moment of extraordinary clinical opportunity. A patient who nearly died hours ago is often more open to starting treatment than they will be at any other moment.

The tragedy is what the research community politely calls the “referral to ongoing treatment” problem. Studies of patients seen in EDs for nonfatal overdose have found that only a minority receive medication for opioid use disorder in the following months, even though a nonfatal overdose is one of the strongest predictors of a subsequent fatal one. The year after a nonfatal overdose is a period of dramatically elevated death risk—and the days immediately after are the worst of all.

The ED can open the door. The system behind the door is often a hallway with a missing floor.

Why Current Systems Fail After Discharge

None of this is because emergency teams don’t care, or because community clinics don’t work hard. The failure is structural, and it repeats in hospital after hospital:

The Appointment Gap

In much of the country, the first available intake at an addiction clinic or office-based buprenorphine practice is one to four weeks out. Opioid withdrawal peaks in 48–72 hours. Asking a patient in escalating withdrawal to wait two weeks is not a plan; it is a prediction of relapse.

High-Threshold Intake

Many programs still require in-person intakes, multiple assessment visits, mandatory counseling enrollment, or drug testing before a prescription. Every added requirement is a step off the path for a patient in crisis. The field’s own data favor “low-threshold” care: start medication first, build the rest around the patient.

Workforce Shortages

Most U.S. counties have no addiction medicine specialist. Psychiatry shortages are severe and worsening; behavioral health vacancies in rural and safety-net settings routinely exceed 20–30%. Even motivated hospitals cannot hire their way out of this.

Geography and Transportation

Rural patients may face a 60–120 minute drive to the nearest prescriber—assuming they have a car, a license, gas money, and a job that tolerates absences. Methadone is even harder: daily visits to a licensed opioid treatment program are simply impossible for much of rural America.

Stigma Inside and Outside Medicine

Patients report that healthcare providers treat them differently once “opioid use disorder” appears on their chart. Some leave against medical advice (AMA) because they fear the medical team will not treat their withdrawal. Some never fill the bridge prescription because the pharmacy interaction feels humiliating.

Fragmented Information

The clinic never learns the patient was in the ED. The ED never learns the patient didn’t show. No one owns the gap, so the gap owns the patient.

Each failure is survivable alone. Stacked together in the worst three days of a person’s life, they are often not.

The 72-Hour Cliff, Explained

The “72-hour cliff” is our name for the collision of three timelines in the days after ED discharge:

1. The withdrawal timeline

Untreated opioid withdrawal from short-acting opioids typically begins within 8–24 hours of last use. It often peaks around 48–72 hours, causing pain, vomiting, diarrhea, insomnia, anxiety, and intense cravings. However, fentanyl complicates this timeline. Its lipophilic accumulation in tissue can make withdrawal timing unpredictable and buprenorphine initiation more difficult. Therefore, patients need fast access to clinicians experienced with modern induction strategies, including low-dose “micro-induction” approaches when appropriate.

2. The tolerance timeline

Opioid tolerance fades within days. After an overdose or a period of abstinence—such as hospitalization, detox, or incarceration—a person may return to an illicit fentanyl supply that their body can no longer tolerate. This is why the weeks after detox discharge and the first two weeks after release from incarceration are among the most lethal windows in all of medicine; studies of post-release populations have found overdose death rates orders of magnitude above baseline.

3. The motivation timeline

Readiness for treatment is not a permanent state; it is a window. The patient who says “yes” to buprenorphine at 3 a.m., hours after nearly dying, may not say yes on day ten, after withdrawal has been survived the only way they know how. Every day between the ED visit and the first follow-up appointment, some fraction of patients falls away—not because they stopped wanting recovery, but because the system asked them to white-knuckle the exact window when their disease is strongest.

Put those three curves on the same axis and the conclusion writes itself: the follow-up appointment must happen within 24–72 hours of discharge. Not within two weeks. Not “as soon as we can get you in.” Within the window. This is the single highest-leverage interval in addiction medicine, and it is precisely the interval our current infrastructure was never built to cover.

Why Patients Relapse After ED Discharge (It’s Not a Willpower Problem)

Families often interpret a relapse three days after an ED visit as a failure of resolve. Clinically, it is closer to a failure of coverage. Opioid use disorder is a chronic brain condition in which the midbrain’s survival circuitry has been retrained to rank opioids alongside food and water. In untreated withdrawal, that circuitry is screaming. Expecting untreated willpower to beat peak withdrawal is like expecting a patient to lower their own blood pressure by concentrating.

Medication changes the equation. Buprenorphine, a partial opioid agonist, relieves withdrawal and craving without the euphoria-and-crash cycle, and its receptor behavior gives it a ceiling on respiratory depression that makes it far safer than full agonists. Patients stabilized on buprenorphine describe something people who haven’t lived this rarely appreciate: the silence. The obsessive noise stops, and planning a life becomes possible again.

But medication only works when the supply of care is continuous. A 3-day bridge prescription with no follow-up scheduled is a fuse, not a bridge. The relapse that follows is predictable pharmacology, not a character verdict.

The Evidence for ED-Initiated Buprenorphine

The trial that changed emergency medicine

In 2015, Gail D’Onofrio and colleagues at Yale published a randomized trial in JAMA comparing three ED strategies for patients with opioid dependence: referral to treatment, a brief intervention with facilitated referral, or ED-initiated buprenorphine with ongoing office-based follow-up. The results were striking: roughly 78% of patients started on buprenorphine in the ED were engaged in treatment at 30 days, versus about 37% with referral alone and 45% with brief intervention. Few single studies have moved a specialty faster.

Two honest caveats matter. First, the advantage attenuated at later time points in follow-up analyses—engagement gaps narrowed by two and six months. Rather than undermining the model, that finding sharpens the lesson: initiation without sustained continuity is not enough. Second, the trial’s buprenorphine arm included something most real-world EDs cannot offer: a guaranteed, rapid, low-friction landing spot for ongoing care. The trial didn’t just test a medication. It tested a bridge.

From trial to movement: CA Bridge and low-threshold care

California’s CA Bridge program (born at Highland Hospital in Oakland) turned the evidence into an implementation playbook now spread across hundreds of hospitals: treat withdrawal aggressively, start buprenorphine in the ED without preconditions, embed substance use navigators, and connect patients to follow-up—a philosophy summarized as low-threshold, high-touch care. Program data and published implementation studies consistently show that when EDs adopt this model, MOUD initiation rises dramatically. And the same literature keeps flagging the same bottleneck: linkage. The “cascade of care” narrows at every step between the ED dose and the 30-day follow-up, and the steepest narrowing happens in the first days.

ED-INNOVATION and extended-release options

The multicenter ED-INNOVATION trial compared standard sublingual buprenorphine with a 7-day extended-release injectable formulation started in the ED. Extended-release buprenorphine is a genuinely useful tool—it buys a patient a week of receptor coverage on the way out the door and is especially attractive when follow-up is uncertain. But a week of medication is a head start, not a destination. Even the best injection eventually asks the same question the sliding doors ask: who is catching this patient on the other side?

The X-waiver is gone

For over two decades, prescribing buprenorphine required a special DEA “X-waiver,” a regulatory scarlet letter that kept most physicians out of addiction treatment. The Consolidated Appropriations Act of 2023 (via the MAT Act) eliminated it. Any clinician with a standard DEA registration can now prescribe buprenorphine for opioid use disorder. The legal barrier is gone; the operational barrier—someone to actually see the patient this week—remains. That is the gap the rest of this article is about.

The Evidence for Telemedicine Addiction Treatment

If ED-initiated buprenorphine is the field’s best-proven start, telemedicine is its best-proven scale. The COVID-19 public health emergency created an unplanned national experiment: for the first time, buprenorphine could be initiated by phone or video without an in-person exam. The results, across multiple large studies, have been consistently reassuring:

Retention Improved or Held Steady

Analyses of Medicare and Medicaid populations found that patients using MOUD through telehealth stayed in treatment more often than comparable patients receiving traditional care. Retention also remains the factor most closely linked to survival in opioid use disorder.

Overdose Risk Did Not Rise—and in Some Cohorts Fell

A widely cited 2022 study of Medicare beneficiaries in JAMA Psychiatry found telehealth-based MOUD associated with improved retention and lower risk of medically treated overdose. Population-level analyses through the flexibility period have not shown the feared surge in buprenorphine-related harms.

Diversion Fears Have Not Materialized at Scale

Buprenorphine’s pharmacology limits its misuse potential, and studies of the telehealth era suggest most “diverted” buprenorphine is used by people trying to treat their own withdrawal—an indictment of access, not of the medication.

Access Expanded Where It Was Thinnest

Telehealth disproportionately reached rural patients, patients without transportation, and patients who had never before engaged in treatment.

Honesty requires the caveats, too. Much of this evidence is observational; telehealth patients differ from in-person patients in ways statistics can only partly adjust for. Telemedicine is not the right modality for every patient—some need in-person examination, some lack phones or privacy, and complex co-occurring conditions may warrant hybrid care. And the regulatory ground is still settling: the DEA has repeatedly extended its telemedicine controlled-substance flexibilities while working toward permanent rules (including proposals specific to buprenorphine and a special telemedicine registration), and requirements can vary by state. Responsible telemedicine organizations track this landscape daily, comply conservatively, and are candid with patients and hospital partners that the rules are evolving. What is not in dispute is the direction of the evidence: for opioid use disorder, fast access beats perfect access, and telemedicine delivers fast.

Real-World Implementation: What a Working ED-to-Telehealth Bridge Looks Like

Having delivered well over 120,000 telemedicine visits—a large share of them for patients other parts of the system struggled to reach—our team has learned that continuity is not a mystery. It is an engineering problem, with knowable failure points and buildable solutions. A functioning bridge has five parts:

A Warm Handoff, Not a Phone Number

Before discharge, the ED team (physician, navigator, case manager, or nurse) connects the patient directly to the follow-up service—a scheduled video visit, a live introduction, or at minimum a confirmed appointment within 24–72 hours, in the patient’s phone, with a human name attached. Discharge paperwork alone converts poorly; a person converts.

A Bridge Prescription That Reaches the Appointment

The ED prescription should cover the patient until the confirmed follow-up—typically 3 to 7 days of buprenorphine—with the pharmacy called ahead when possible. Extended-release injectable buprenorphine can serve the same function where available.

A First Virtual Visit Inside the Window

Same-day or next-day, with an addiction-experienced physician: verify the induction went well, manage precipitated-withdrawal fears, adjust dosing (fentanyl-era patients often need more than legacy dosing guidance suggests), prescribe naloxone, and set the next touchpoint before the visit ends.

High-Frequency Early Contact

Weeks one through four are the fragile period. Short, frequent check-ins—clinician visits plus text-based nudges—outperform infrequent long ones. Missed-visit outreach must be automatic and shame-free; a no-show is clinical data, not a discharge criterion.

A Road That Continues

Stabilization into ongoing MOUD care, counseling and peer support offered (not mandated), attention to the social determinants that actually drive relapse—housing, transportation, employment, child care—and coordination back to primary care. Low-threshold does not mean low-expectation; it means the expectations are sequenced to the patient’s physiology instead of the clinic’s paperwork.

None of these steps is exotic. What is rare is an entity accountable for all five at once. That accountability—the “catch” on the far side of the ED’s throw—is the missing organ of the American addiction treatment system.

The Barriers, Honestly Assessed

Hospital barriers

Emergency departments are asked to fix in a shift what the system breaks over years. Real constraints include boarding and throughput pressure that make any added workflow feel impossible. In addition, attending and nursing turnover can erode protocol knowledge. At night, the absence of navigators or social work coverage creates another barrier, especially when overdose patients are most likely to present. Medical staff may also feel anxious about induction in patients using fentanyl. Meanwhile, quality dashboards have historically measured what happened during the visit, not whether the patient survived the following month.

As a result, champions burn out when every referral they make evaporates into a two-week waitlist. Therefore, the fastest way to sustain an ED buprenorphine program is to make the referral actually work. Clinicians are more likely to take the extra steps when they see the catch happen.

Rural barriers

Rural America has the country’s highest overdose death rates in many regions and its thinnest treatment infrastructure: counties with zero buprenorphine prescribers, opioid treatment programs hours away, pharmacy deserts, and critical access hospitals with no behavioral health staff at all. Broadband gaps are real but shrinking, and audio-only allowances have mattered enormously here. Telemedicine is not merely convenient in rural settings—it is frequently the only mathematically possible way to put an addiction-trained physician in front of a patient inside the 72-hour window.

Behavioral health barriers

The behavioral health workforce shortage is a decade-deep hole: psychiatrist retirements outpacing training pipelines, months-long waits for therapy, and community mental health centers triaging crisis over continuity. Patients with opioid use disorder commonly carry co-occurring depression, anxiety, PTSD, or stimulant use—conditions that untreated, quietly pull medication adherence apart. Any serious continuity model must integrate behavioral health rather than referring into the same void that swallowed the original addiction referral.

Justice-involved patients

The hardest version of the cliff belongs to people leaving jails and prisons. Forced abstinence erases tolerance; release into instability does the rest. Landmark research on post-incarceration mortality found overdose death risk in the first two weeks after release elevated by an order of magnitude or more compared with the general population. Drug courts, reentry programs, and correctional health systems increasingly want MOUD continuity—but the community handoff fails for justice-involved patients even more often than for ED patients, compounded by ID loss, Medicaid churn at release, and supervision requirements that conflict with clinic hours. Telemedicine can reach people the day they walk out with nothing but a phone, making it especially well suited to this population. Partnerships between virtual addiction medicine practices and correctional or court systems also rank among the highest-impact collaborations in the field.

How Telemedicine Changes the Outcome

Look back at every failure mode above and notice what they share: time and distance. The clinic is too far. The intake is too late. The counselor is three counties away. The prescriber works banker’s hours. Telemedicine does not make addiction easier to treat—it makes treatment easier to reach, and in a disease where the fatal window is measured in days, reach is outcome.

• It collapses the appointment gap. A virtual practice with adequate physician coverage can see an ED-discharged patient the same day, seven days a week. The two-week intake becomes a two-hour one.
• It collapses geography. The patient in a town of 900 sees the same addiction-experienced physician as the patient in a metro area. Multi-state licensure lets one clinical team backstop hospitals across entire regions.
• It lowers the threshold without lowering the standard. No waiting rooms, no bus transfers, no walking past people you used with. Care meets patients in their kitchen—which is also where honest conversations about triggers, housing, and family actually happen.
• It makes frequency affordable. Fifteen-minute video check-ins twice a week in the fragile first month are operationally trivial by telehealth and nearly impossible in brick-and-mortar workflows.
• It survives the patient’s chaos. Missed visit? The reschedule is tonight, not next month. Moved two counties over? The care moves too. Lost the car? Irrelevant.

The point deserves restating because it is the crux of this entire subject: telemedicine is not competing with the emergency department, and it is not competing with community clinics. The ED starts treatment better than anyone. Local programs and counselors provide depth no video visit replaces. Telemedicine’s role is the connective tissue—the rapid, reliable span between the heroic start and the long middle. It completes the system that already exists.

How Physician-Led Continuity Works

A word about who should run this bridge, because it matters more than the technology. Addiction medicine in the fentanyl era is clinically demanding: unpredictable withdrawal, precipitated-withdrawal management, micro-induction strategies, complex psychiatric comorbidity, pregnancy, pain, polysubstance use. It is also trust-dependent in a way few specialties are—these patients have been dismissed, lectured, and discharged-to-nowhere before, and they can detect an assembly line instantly.

Physician-led means the model is designed by clinicians who have managed these patients at the bedside, that protocols follow evidence rather than growth targets, that every patient has a physician who knows their story, and that the measure of success is retention and survival, not visit volume. Our own conviction on this point comes from experience on both sides of the handoff: years in the emergency department watching patients disappear off the cliff, and years—and more than 120,000 virtual visits—learning what it takes to catch them. The single most reliable lesson from that experience is unglamorous: speed and follow-through beat everything else. The practice that answers today outperforms the prestigious program that answers in three weeks, every time.

Two Patients, Two Outcomes (Composite Stories)

The following are fictional composites drawn from common clinical patterns. They do not describe real, identifiable patients.

Marcus, 34 — the cliff

Paramedics revive Marcus with naloxone in a suburban ED after a fentanyl overdose. The medical team starts him on buprenorphine. By morning, he feels human again and leaves with a referral to a clinic that offers an intake in eleven days. By day three, withdrawal returns and the bridge prescription is gone. He uses “just to get through the weekend”—at his old dose, with his new tolerance. His story is the statistics in this article wearing a face; the system did not fail to treat him, it failed to keep treating him for eleven days.

Dana, 41 — the bridge

Dana arrives at a rural critical access hospital in withdrawal, asking for help. The ED starts buprenorphine and, before discharge, a nurse sits with her while she books a video visit for the next morning with a telemedicine addiction physician the hospital partners with. The physician adjusts her dose on day one, sees her twice in week one, connects her to virtual counseling in week two, and coordinates with her pharmacy forty minutes away. At day 30 she is retained in care; at month six the visits are monthly and she has her job back. Nothing about Dana’s care was heroic. It was merely continuous—and continuity, in this disease, is the miracle.

For Hospitals and Health Systems

This section is for emergency physicians, medical directors, behavioral health leaders, case management, population health teams, and executives who own the numbers that the 72-hour cliff quietly destroys.

The metrics that move

A reliable ED-to-telehealth bridge is not a feel-good add-on; it is an operational intervention with measurable targets:

• MOUD initiation rates. ED buprenorphine programs stall when clinicians watch their referrals evaporate. A guaranteed 24–72 hour landing spot is the single strongest sustainer of ED initiation—and ED MOUD measures are increasingly visible in quality frameworks and payer scorecards.
• Readmissions and repeat ED utilization. Patients with untreated OUD are among the highest-frequency ED utilizers in any system. Retention in MOUD is associated with substantial reductions in acute care use; closing the follow-up gap attacks readmissions at the root rather than at the discharge-lounge margin.
• AMA discharges. A meaningful share of AMA departures among patients who use opioids are driven by untreated withdrawal and hopelessness about what comes next. Aggressive withdrawal management plus a concrete, near-term follow-up plan changes that calculus at the bedside.
• ED boarding of behavioral health patients. When the community disposition options are “nothing for two weeks,” patients board. A virtual addiction medicine partner expands disposition options without adding beds.
• Mortality and community standing. Post-overdose death within a year of an ED visit is common enough to be a system-level quality issue. Hospitals that visibly close this loop earn trust with EMS, county health, and the recovery community that no marketing budget can buy.

Why partnership beats building it alone

Some large academic systems have built superb internal bridge clinics. However, they remain the exception. The model requires addiction-trained clinicians, seven-day scheduling capacity, telehealth licensure, compliance infrastructure, and payer contracting. Most hospitals, especially rural and critical access facilities, cannot staff all of these needs. Psychiatry recruitment timelines run years. The cliff runs 72 hours. A telemedicine partnership inverts the problem. The hospital contributes the moment of engagement and the warm handoff. The virtual practice contributes physicians, capacity, multi-state coverage, and accountability for what happens next. The fixed cost of “build” becomes the variable cost of “connect.”

What implementation actually requires

In our experience, standing up a functioning bridge with a hospital partner is measured in weeks, not fiscal years, and looks like this:

• An ED protocol and order set for withdrawal management and buprenorphine initiation (CA Bridge’s open resources are an excellent starting scaffold), with fentanyl-era dosing guidance.
• A one-step referral pathway—a QR code on discharge paperwork at minimum, a scheduled video visit or live warm handoff before the patient leaves at best—available at 2 a.m., because that is when the patients are.
• A defined bridge-prescription practice so every referred patient is covered until the confirmed visit.
• A feedback loop. The virtual partner reports back: who connected, who was retained at 7/30/90 days, who needs re-engagement. The ED finally sees its saves. Champions stop burning out.
• Clear governance on compliance, credentialing, data sharing, and escalation pathways back to in-person care when patients need it.

For population health and ACO leaders, the same pathway applies beyond the emergency department. Hospital discharge, post-detox, obstetric, and post-surgical populations all face versions of the cliff. For state opioid response programs, FQHCs, employers, and correctional systems, physician-led virtual addiction medicine offers a rare solution. It is evidence-aligned, fast to deploy, and scalable across geographic areas. If your organization is struggling with any version of this handoff, we are always glad to discuss what breaks, where it happens, and how other systems have closed the gap.

Beyond Addiction: Integrated Virtual Care, TelePrEP, and TelePEP

Opioid use disorder rarely travels alone, and a bridge that only carries one diagnosis drops the rest of the patient. People who inject drugs face a sharply elevated risk of HIV and hepatitis C. Recent outbreak clusters in the United States have repeatedly been traced to injection networks in communities with the least infectious disease infrastructure. This is why integrated virtual care matters:

• TelePrEP brings HIV pre-exposure prophylaxis—among the most effective preventives in modern medicine—to patients who will never present to a sexual health clinic, with home or local lab testing and virtual follow-up.
• TelePEP delivers post-exposure prophylaxis inside its urgent 72-hour initiation window (a different 72-hour cliff, with the same lesson: speed is the treatment).
• Virtual behavioral health treats the depression, anxiety, and PTSD that drive relapse when ignored.
• Virtual primary care and urgent care handle the hypertension, the infected skin wound, the prescription refill—the ordinary medicine that keeps patients engaged and out of the ED.

Fragmentation is not just inefficient; it is clinically dangerous, because every additional handoff between siloed providers is another cliff edge. When addiction medicine, infectious disease prevention, behavioral health, and everyday care exist within one physician-led virtual practice, patients tell their story once. The chart is whole, and no referral disappears into the void. That is the quiet endgame of the bridge model. It is not a Suboxone dispensary with a video screen. Instead, it is a front door to complete care for patients the system has historically failed.

Frequently Asked Questions

The Bridge Is Buildable: A Closing Word

Everything in this article reduces to a short story. American emergency departments learned, over one hard decade, how to start treating addiction in the moment it presents itself. That was the difficult part, and it is largely done. What remains is shorter, cheaper, and entirely solvable: making sure that every patient who starts has somewhere to land within 72 hours. The evidence exists. The medications exist. The regulations, for all their motion, now permit it. The technology sits in every patient’s pocket.

Recovery is not rare. Tens of millions of Americans are living in recovery right now, and most of them once sat where the patient in the opening paragraph sat—discharge papers in hand, dawn coming up, odds unspoken. What separated the ones who made it was rarely willpower and almost always this: someone caught them in time, and kept showing up.

Technology should reconnect people, not replace them. A video visit is not the point; the physician on the other side of it—who knows your name, expects you Thursday, and calls when you miss—is the point. Medicine works best when physicians and patients build trust together, and it turns out trust travels just fine over a phone signal, as long as it arrives on time.

The emergency department starts the treatment. The bridge completes it. And the bridge is buildable—we know, because we spend every day building it.

If you’re a patient standing at the edge of your own 72 hours: help is closer than it has ever been, often just a same-day appointment away. If you’re a hospital, health system, or community organization tired of watching good starts fall off the cliff, partner with us, and let’s talk about closing your gap.

With hope, and from experience—

— The DevotedDOC